drugset / Trial / NCT06916065
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much eloralintide and eloralintide with tirzepatide get into the bloodstream and how long it takes the body to eliminate it. There will be 6 cohorts. The study will last up to approximately 26 weeks, excluding screening for Cohorts A and B, 11 weeks for Cohorts C and D, and 12 weeks for Cohorts E and F.
Timeline
- Start
- 2025-04-09
- Primary completion
- 2026-01-19
- Completion
- 2026-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eloralintide | Protein / enzyme biologic | — | Subcutaneous |
| Subject | Tirzepatide | Peptide | — | Subcutaneous |